Yahoo Finance

• Sales Revenue: JPY1,904.8 billion, an increase of JPY98 billion year over year.

• Core Operating Income: JPY60.1 billion, up JPY173.9 billion year on year.

• Net Income Attributable to Owners of Parent: JPY28.6 billion, an improvement of JPY138.4 billion year on year.

• Operating Income: JPY145.4 billion, a large improvement of JPY306.1 billion year on year.

• Interest Bearing Liabilities: JPY1,443.7 billion, a decrease of JPY119.8 billion compared to the end of the previous fiscal year.

• Cash Flows from Operating Activities: JPY140.7 billion inflow, an increase of JPY275.7 billion year on year.

• Free Cash Flow: Positive JPY197.5 billion, an improvement of JPY410.2 billion compared to the previous fiscal year.

• Agro & Life Solutions Core Operating Income: JPY19.5 billion, improvement of JPY22.4 billion year on year.

• ICT and Mobility Solutions Core Operating Income: JPY59.7 billion, up JPY15.8 billion year on year.

• Advanced Medical Solutions Core Operating Income: JPY1.9 billion, down JPY1.8 billion year on year.

• Essentials and Green Material Core Operating Income: Loss of JPY44.3 billion, an improvement of JPY16.2 billion year on year.

• Sumitomo Pharma Core Operating Income: JPY19.9 billion, a significant improvement of JPY116.2 billion year on year.

• Warning! GuruFocus has detected 7 Warning Signs with SOMMF.

Release Date: February 03, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Core operating income for the third quarter improved significantly, with a profit of JPY60.1 billion compared to a loss of JPY113.9 billion in the same period last year.

• Sales revenue increased by JPY98 billion year over year, reaching JPY1,904.8 billion.

• The company achieved a net income attributable to owners of the parent of JPY28.6 billion, an improvement of JPY138.4 billion year on year.

• Sumitomo Pharma's core operating income saw a significant improvement of JPY116.2 billion year on year.

• Free cash flow was positive JPY197.5 billion, an improvement of JPY410.2 billion compared to the previous fiscal year.

Negative Points

• Non-recurring items posted losses, including Sumitomo Pharma's North America business restructuring cost of JPY14.8 billion and impairment loss of JPY5.5 billion.

• The essentials and green material segment reported a core operating income loss of JPY44.3 billion, despite an improvement year on year.

• The Advanced Medical Solutions segment saw a decline in core operating income by JPY1.8 billion year on year.

• The company faced a temporary loss of JPY23.8 billion related to the loan to Petro Rabigh.

• The forecast for the full year remains unchanged despite potential upside, indicating ongoing uncertainties and lower predictability.